Focused ultrasound for targeted delivery of siRNA and efficient knockdown of Htt expression.
Authors: Burgess A, Huang Y, Querbes W, Sah DW, Hynynen K
RNA interference is a promising strategy for the treatment of Huntington's disease (HD) as it can specifically decrease the expression of the mutant Huntingtin protein (Htt). However, siRNA does not cross the blood-brain barrier and therefore delivery to the brain is limited to direct CNS delivery. Non-invasive delivery of siRNA through the blood-brain barrier (BBB) would be a significant advantage for translating this therapy to HD patients. Focused ultrasound (FUS), combined with intravascular delivery of microbubble contrast agent, was used to locally and transiently disrupt the BBB in the right striatum of adult rats. 48h following treatment with siRNA, the right (treated) and the left (control) striatum were dissected and analyzed for Htt mRNA levels. We demonstrate that FUS can non-invasively deliver siRNA-Htt directly to the striatum leading to a significant reduction of Htt expression in a dose dependent manner. Furthermore, we show that reduction of Htt with siRNA-Htt was greater when the extent of BBB disruption was increased. This study demonstrates that siRNA treatment for knockdown of mutant Htt is feasible without the surgical intervention previously required for direct delivery to the brain.
Introduction
Purpose
Drug delivery with BBB opening
Study Objective
To determine whether focused ultrasound–mediated transient disruption of the blood–brain barrier can noninvasively deliver siRNA targeting Huntingtin to the striatum and reduce Htt expression in rats.
Animal model / Human subject
Rat, strain not specified, adult, sex not specified
Disease model
Huntington's disease
MRI or image guidance method
MRI-guided
Targeted brain region(s)
Striatum
Cargo name and characteristics
siRNA-Htt (small interfering RNA targeting Huntingtin mRNA; synthetic RNA oligonucleotide for RNA interference-mediated knockdown)
Route of administration
Intravenous (intravascular/systemic delivery)
Outcomes and Safety
Summary of Outcomes
Focused ultrasound (with intravascular microbubbles) enabled noninvasive delivery of siRNA-Htt to the rat striatum, producing a significant, dose-dependent reduction in Htt mRNA; greater Htt knockdown was achieved when FUS produced increased blood–brain barrier disruption.
Duration of biological effect
48 hrs
Safety-related matter
The provided excerpt contains no mention of safety assessments, adverse effects, or toxicity related to the focused ultrasound or siRNA treatment; the authors did not report either observed adverse effects or an explicit statement of their absence.
Brain Region
Ultrasound Parameters
Ultrasound instrument
MRIgFUS
FUS Frequency
558 kHz
FUS Pressure
0.3 Mpa
FUS Mode
pulsed
Pulse duration
10 ms
Duration of a single FUS session
120 s (2 minutes)
Focal Characteristics
Focal depth: None; Focal length: None; Aperture size: None
Treatment frequency
multiple sessions
We are open to feedback. If you see a mistake or have a suggestion, please contact us.
← Back to Search